免疫学
单克隆抗体
B细胞
医学
疾病
美罗华
细胞
治疗方法
自身免疫性疾病
CD20
抗体
生物
内科学
遗传学
作者
Étienne Crickx,Jean–Claude Weill,Claude–Agnès Reynaud,Matthieu Mahévas
标识
DOI:10.1016/j.kint.2019.12.025
摘要
B-cell depletion with anti-CD20 monoclonal antibodies is widely used for the treatment of autoimmune diseases. This review will discuss mechanisms contributing to success or failure of B-cell depletion therapy in antibody-mediated autoimmune diseases. It will also explain how key information about disease pathogeny can be provided by the different outcomes observed after B-cell depletion therapy. These findings provide the basis for future innovative therapeutic strategies aiming at an optimized B cell and/or plasma cell depletion to increase long-term disease remission. B-cell depletion with anti-CD20 monoclonal antibodies is widely used for the treatment of autoimmune diseases. This review will discuss mechanisms contributing to success or failure of B-cell depletion therapy in antibody-mediated autoimmune diseases. It will also explain how key information about disease pathogeny can be provided by the different outcomes observed after B-cell depletion therapy. These findings provide the basis for future innovative therapeutic strategies aiming at an optimized B cell and/or plasma cell depletion to increase long-term disease remission.
科研通智能强力驱动
Strongly Powered by AbleSci AI